UPS plans to invest $48m in temperature-controlled facilities to accommodate shipping weight-loss drugs (opens original article in a new tab)

UPS is investing $48 million in temperature-controlled facilities to meet growing demand for weight-loss drugs and other medications, as GLP-1 drug usage rises among Americans and the biologics transportation market expands.

• UPS plans to invest $48 million in 27 temperature-controlled facilities to handle demand for weight-loss drugs
• GLP-1 drugs are taken by 12% of Americans currently and 18% at some point
• UPS reports $3 billion in healthcare revenue in first quarter of 2025
• Global biologics transportation market was $19.7 billion in 2024 and expected to reach $39.1 billion by 2033